ASTRAZENECA PLC ADR

NASDAQ: AZN (Astrazeneca PLC)

Kemas kini terakhir: 4 hari lalu, 1:51PM

90.86

0.69 (0.76%)

  • 1H 0.76%
  • 5H -2.56%
  • 1B 7.42%
  • 6B 24.44%
  • Tahun Ke Tarikh 37.91%
  • 1T 32.48%
  • 5T 67.44%
Penutupan Terdahulu 90.17
Buka 90.69
Jumlah Dagangan 4,323,866
Purata Dagangan (3B) 5,064,657
Modal Pasaran 281,702,039,552
Harga / Pendapatan (P/E TTM) 30.18
Harga / Pendapatan (P/E Ke hadapan) 18.02
Harga / Jualan (P/S) 4.98
Harga / Buku (P/B) 6.26
Julat 52 Minggu
61.24 (-32%) — 94.02 (3%)
Tarikh Pendapatan 6 Nov 2025
Hasil Dividen (DY TTM) 1.72%
Margin Keuntungan 14.14%
Margin Operasi (TTM) 27.94%
EPS Cair (TTM) 2.48
Pertumbuhan Hasil Suku Tahunan (YOY) 7.20%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 33.80%
Jumlah Hutang/Ekuiti (D/E MRQ) 77.11%
Nisbah Semasa (MRQ) 0.900
Aliran Tunai Operasi (OCF TTM) 13.09 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 9.35 B
Pulangan Atas Aset (ROA TTM) 8.16%
Pulangan Atas Ekuiti (ROE TTM) 19.79%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menurun
Drug Manufacturers - General (Global) Menaik Menurun
Stok Astrazeneca PLC Bercampur Bercampur

AISkor Stockmoo

0.5
Konsensus Penganalisis 2.0
Aktiviti Orang Dalam NA
Volatiliti Harga -3.0
Purata Bergerak Teknikal -1.0
Osilator Teknikal 4.0
Purata 0.50

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
AZN 282 B 1.72% 30.18 6.26
SNY 121 B 4.45% 16.36 1.41
AMGN 182 B 2.82% 26.13 19.34
GILD 154 B 2.55% 19.24 7.32
GRFS 7 B 1.96% 14.05 0.960
BIIB 27 B - 16.61 1.42

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Growth
% Dimiliki oleh Institusi 17.13%

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
02 Dec 2025 Pengumuman Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
26 Nov 2025 Pengumuman IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
21 Nov 2025 Pengumuman AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth
09 Nov 2025 Pengumuman Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
07 Nov 2025 Pengumuman Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease
06 Nov 2025 CNBC Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
06 Nov 2025 Pengumuman Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
06 Nov 2025 Pengumuman AstraZeneca's 9M and Q3 2025 Financial Results
29 Oct 2025 CNBC Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound
19 Oct 2025 Pengumuman DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
18 Oct 2025 Pengumuman ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
18 Oct 2025 Pengumuman ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
17 Oct 2025 Pengumuman IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial
17 Oct 2025 Pengumuman IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
17 Oct 2025 Pengumuman TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
17 Oct 2025 CNBC Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
15 Oct 2025 Pengumuman AstraZeneca unveils expanded manufacturing facility in Texas
13 Oct 2025 Pengumuman AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
10 Oct 2025 CNBC Trump reaches deal with AstraZeneca to lower U.S. drug prices
09 Oct 2025 Pengumuman Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery
09 Oct 2025 Pengumuman AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
07 Oct 2025 Pengumuman Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
06 Oct 2025 Pengumuman DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02
29 Sep 2025 Pengumuman ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial
26 Sep 2025 Pengumuman AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions
24 Sep 2025 Pengumuman ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
22 Sep 2025 Pengumuman SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
18 Sep 2025 Pengumuman AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol
17 Sep 2025 Pengumuman Advancing Cancer Research Brings New Hope for Patients Worldwide
17 Sep 2025 Pengumuman SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
07 Sep 2025 Pengumuman TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer
Papar semua
Hasil Dividen (DY TTM) 1.72%
Purata Hasil Dividen 5T 2.35%
Nisbah Pembayaran 62.37%
Jangkaan Pembayaran Dividen Seterusnya Mar 2026
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
08 Aug 2025 29 Jul 2025 08 Sep 2025 0.515 Tunai
21 Feb 2025 06 Feb 2025 24 Mar 2025 1.05 Tunai
09 Aug 2024 25 Jul 2024 09 Sep 2024 0.5 Tunai
22 Feb 2024 08 Feb 2024 25 Mar 2024 0.985 Tunai
10 Aug 2023 28 Jul 2023 11 Sep 2023 0.465 Tunai
23 Feb 2023 09 Feb 2023 27 Mar 2023 0.985 Tunai
11 Aug 2022 29 Jul 2022 12 Sep 2022 0.465 Tunai
24 Feb 2022 10 Feb 2022 28 Mar 2022 0.985 Tunai
12 Aug 2021 29 Jul 2021 13 Sep 2021 0.45 Tunai
25 Feb 2021 11 Feb 2021 29 Mar 2021 0.95 Tunai
13 Aug 2020 30 Jul 2020 14 Sep 2020 0.45 Tunai
27 Feb 2020 14 Feb 2020 30 Mar 2020 0.95 Tunai
08 Aug 2019 29 Jul 2019 09 Sep 2019 0.45 Tunai
28 Feb 2019 14 Feb 2019 27 Mar 2019 0.95 Tunai
09 Aug 2018 26 Jul 2018 10 Sep 2018 0.45 Tunai
15 Feb 2018 02 Feb 2018 19 Mar 2018 0.95 Tunai
09 Aug 2017 28 Jul 2017 11 Sep 2017 0.45 Tunai
15 Feb 2017 02 Feb 2017 20 Mar 2017 0.95 Tunai
10 Aug 2016 28 Jul 2016 12 Sep 2016 0.45 Tunai
17 Feb 2016 05 Feb 2016 21 Mar 2016 0.95 Tunai
12 Aug 2015 30 Jul 2015 14 Sep 2015 0.45 Tunai
18 Feb 2015 09 Feb 2015 23 Mar 2015 1.9 Tunai
13 Aug 2014 31 Jul 2014 15 Sep 2014 0.9 Tunai
19 Feb 2014 07 Feb 2014 24 Mar 2014 1.9 Tunai
14 Aug 2013 01 Aug 2013 16 Sep 2013 0.9 Tunai
13 Feb 2013 31 Jan 2013 18 Mar 2013 1.9 Tunai
08 Aug 2012 26 Jul 2012 10 Sep 2012 0.9 Tunai
15 Feb 2012 02 Feb 2012 19 Mar 2012 1.95 Tunai
04 Aug 2011 28 Jul 2011 12 Sep 2011 0.85 Tunai
02 Feb 2011 27 Jan 2011 14 Mar 2011 1.85 Tunai
04 Aug 2010 29 Jul 2010 13 Sep 2010 0.7 Tunai
03 Feb 2010 28 Jan 2010 15 Mar 2010 1.71 Tunai
05 Aug 2009 30 Jul 2009 14 Sep 2009 0.59 Tunai
04 Feb 2009 29 Jan 2009 16 Mar 2009 1.5 Tunai
06 Aug 2008 31 Jul 2008 15 Sep 2008 0.55 Tunai
07 Feb 2008 04 Feb 2008 17 Mar 2008 1.35 Tunai
08 Aug 2007 27 Jul 2007 17 Sep 2007 0.52 Tunai
07 Feb 2007 01 Feb 2007 19 Mar 2007 1.23 Tunai
09 Aug 2006 27 Jul 2006 18 Sep 2006 0.49 Tunai
08 Feb 2006 02 Feb 2006 20 Mar 2006 0.92 Tunai
10 Aug 2005 29 Jul 2005 19 Sep 2005 0.38 Tunai
09 Feb 2005 27 Jan 2005 21 Mar 2005 0.645 Tunai
11 Aug 2004 22 Jul 2004 20 Sep 2004 0.295 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 1.57 2 1.72
2024 1.49 2 2.27
2023 1.45 2 2.15
2022 1.45 2 2.14
2021 1.40 2 2.40
2020 1.40 2 2.80
2019 1.40 2 2.81
2018 1.40 2 3.69
2017 1.40 2 4.04
2016 1.40 2 5.12
2015 2.35 2 6.92
2014 2.80 2 7.96
2013 2.80 2 9.43
2012 2.85 2 12.06
2011 2.70 2 11.67
2010 2.41 2 10.44
2009 2.09 2 8.91
2008 1.90 2 9.26
2007 1.75 2 8.17
2006 1.41 2 5.27
2005 1.03 2 4.22
2004 0.295 1 1.62
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda